Taken together, clinical experience with PD-1/PD-L1 and CTLA-4 blockade in lung cancer, breast cancer, esophageal cancer, and thymoma has established immune checkpoint inhibition as a cornerstone of systemic therapy for thoracic malignancies. The gene discussed is CD274; the disease is breast carcinoma.